Program
abefolastat tesaroxetan CU-64
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Clarity Pharmaceuticals.
Furthest: phase 3, since Sep 21, 20235 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Clarity Pharmaceuticals | 53 open or running | phase 3since Sep 21, 2023 | Apr 7, 2021 | Dec 31, 2026phase 3 · NCT06970847 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2021First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04839367 · 30 enrolled · Australia
- Apr 15, 2021Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT04868604 · 54 planned · United States
- Feb 2, 2022Phase 2 study in Biochemical Recurrence of Malignant Neoplasm of ProstateNCT05249127 · 52 enrolled · United States
- Sep 21, 2023Phase 3 study in Prostatic NeoplasmsNCT06056830 · 383 planned · United States, Australia, Puerto Rico
- Apr 29, 2025Phase 3 study in Prostatic NeoplasmsNCT06970847 · 220 enrolled · United States, Australia
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Prostatic NeoplasmsNCT06970847
TargetBeta
FOLH1 →read by rule
“A radioconjugate composed of abefolastat tesaroxetan, two human prostate-specific membrane antigen (PSMA) binding motifs ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06970847Prostatic Neoplasms · United States, Australia | 3 | Active, not recruiting | Dec 31, 2026 | 220 |
| NCT06056830Prostatic Neoplasms · United States, Australia, Puerto Rico | 3 | Recruiting | Sep 2026 | 383 |
| NCT05249127Biochemical Recurrence of Malignant Neoplasm of Prostate · United States | 2 | Completed | Aug 8, 2023 | 52 |
| NCT04868604Prostatic Neoplasms, Castration-Resistant · United States | 2 | Recruiting | Sep 2026 | 54 |
| NCT04839367Prostatic Neoplasms · Australia | 1 | Completed | Oct 19, 2022 | 30 |
How it is read
Names in the registry
- “64Cu-SAR-bisPSMA”, 5 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.